Table 3.
Risk Factors Predicting Mobilization Failure In Patients Who Received And Those Who Did Not Receive Lenalidomide
|
Lenalidomide used |
Lenalidomide not used |
|||||||
|---|---|---|---|---|---|---|---|---|
| N | N failed | % failed |
P | N | N failed |
% failed |
P | |
| 64 | 16 | 25% | 238 | 10 | 4% | |||
| Age | ||||||||
| ≤60 years | 34 | 5 | 15% | 137 | 6 | 4% | ||
| >60 years | 30 | 11 | 37% | 0.05 | 101 | 4 | 4% | 0.9 |
| Prior chemo regimens | ||||||||
| ≤1 | 31 | 4 | 13% | 155 | 5 | 3% | ||
| >1 | 33 | 12 | 36% | 0.04 | 82 | 5 | 6% | 0.3 |
| Previous radiation | ||||||||
| Yes | 24 | 5 | 21% | 66 | 4 | 6% | ||
| No | 40 | 11 | 28% | 0.5 | 172 | 6 | 3% | 0.4 |
| Interval between diagnosis and mobilization | ||||||||
| ≤12 months | 40 | 6 | 15% | 197 | 5 | 3% | ||
| >12 months | 24 | 10 | 42% | 0.02 | 41 | 5 | 12% | 0.01 |
| White blood cell count (× 109/Liter) | ||||||||
| ≤4 | 14 | 3 | 21% | 27 | 3 | 11% | ||
| >4 | 50 | 13 | 26% | 0.7 | 210 | 7 | 3% | 0.07 |
| ≤5.7 (median) | 38 | 9 | 24% | 114 | 8 | 7% | ||
| >5.7 | 26 | 7 | 27% | 0.8 | 123 | 2 | 2% | 0.06 |
| Platelet count (× 109/Liter) | ||||||||
| ≤262 (median) | 36 | 11 | 31% | 114 | 6 | 5% | ||
| >262 | 28 | 5 | 18% | 0.2 | 123 | 4 | 3% | 0.4 |
| ≤150 | 8 | 2 | 25% | 16 | 1 | 6% | ||
| >150 | 56 | 14 | 25% | 0.9 | 221 | 9 | 4% | 0.7 |
| Cellularity | ||||||||
| ≤30% | 27 | 6 | 22% | 110 | 5 | 5% | ||
| >30% | 36 | 9 | 25% | 0.8 | 128 | 5 | 4% | 0.8 |
| ≤35% (med) | 32 | 8 | 25% | 127 | 5 | 4% | ||
| >35% | 31 | 7 | 23% | 0.8 | 111 | 5 | 5% | 0.8 |
| Lenalidomide cycles | ||||||||
| 1–3 | 55 | 9 | 16% | NA | NA | NA | ||
| >3 | 9 | 7 | 78% | 0.001 | NA | NA | NA | |
| Interval between stopping lenalidomide and mobilization | ||||||||
| ≤9 days | 18 | 5 | 28% | NA | NA | NA | ||
| 10–17 days | 15 | 4 | 27% | 0.9 | NA | NA | NA | |
| 18–46 days | 13 | 2 | 15% | 0.4 | NA | NA | NA | |
| >46 days | 17 | 4 | 24% | 0.8 | ||||